|
|
|
|
||
ASCOOutcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma (LBCL) https://meetinglibrary.asco.org/record/171950/abstract End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) https://meetinglibrary.asco.org/record/173638/abstract ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) https://meetinglibrary.asco.org/record/177917/abstract ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL) https://meetinglibrary.asco.org/record/177950/abstract |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
11870 | Re: ASCO | spaddy | 1 | 4/18/2019 9:44:20 PM |
11873 | Re: ASCO | captsolo | 0 | 4/26/2019 9:55:08 AM |
11877 | Re: ASCO | clsm | 1 | 5/3/2019 3:59:14 PM |